Harrow Inc
NASDAQ:HROW 4:00:00 PM EDT
| Market Cap (Intraday) | 1.77B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | 64.61 |
| 10-Day MA | $46.33 |
| 50-Day MA | $38.60 |
| 200-Day MA | $20.16 |
Harrow Inc Stock, NASDAQ:HROW
102 Woodmont Boulevard, Suite 610, Nashville, Tennessee 37205
United States of America
Phone: +1.615.733.4730
Number of Employees: 315
Description
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.